FDA panel narrowly backs multi-cancer blood test despite doubts it works

A blood test that aims to catch more than 50 types of cancer before symptoms appear narrowly won the backing of U.S. Food and ...

This Controversial Cancer Test Just Passed a Key FDA Vote. Here’s Why It’s Dividing Experts

Grail’s Galleri test costs $1,000 and promises comprehensive early-stage screening for more than 50 types of cancer.
Becker's Hospital Review

FDA panel backs first multi-cancer blood test: What to know

FDA panel backs first multi-cancer blood test, Galleri, confirming safety and recommending continued routine screenings for adults 50 and older.

Largest Real-World Evidence Study in Early-Stage Breast Cancer; FLEX Surpasses 25,000 Patients

Agendia’s landmark FLEX Study reaches a major enrollment milestone, accelerating real-world insights to advance more personalized breast cancer care ...

FDA panel endorses first-of-a-kind cancer blood test

Grail Inc.’s Galleri test doesn't diagnose cancer but instead looks for a signal that someone may have one of a long list of tumors.
KVPR

FDA advisory panel recommends a first: multi-cancer blood test

The company Grail says its Galleri blood test can detect up to 50 forms of cancer. An independent panel of experts weighed ...

FDA panel puts Grail’s cancer screening to the test

A panel of outside advisers will vote this week on whether to recommend that the Food and Drug Administration grant the first ...